Metformin Promotes Anti-tumor Biomarkers in Human Endometrial Cancer Cells

• Published in: Reproductive sciences (Thousand Oaks, Calif.) Vol. 27; no. 1; pp. 267 - 277
• Main Authors: Pabona, John Mark P, Burnett, Alexander F, Brown, Dustin M, Quick, Charles M, Simmen, Frank A, Montales, Maria Theresa E, Liu, Shi J, Rose, Tyler, Alhallak, Iad, Siegel, Eric R, Simmen, Rosalia CM
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 2020
• Subjects: Apoptosis - drug effects; Biomarkers, Tumor; Cell Proliferation - drug effects; Embryology; Endometrial Neoplasms - metabolism; Endometrial Neoplasms - pathology; Endometrial Neoplasms - surgery; Endometrium; Estrogen Receptor alpha - metabolism; Female; Humans; Hypoglycemic Agents - pharmacology; Kruppel-Like Transcription Factors - metabolism; Medicine; Medicine & Public Health; Metformin - pharmacology; Middle Aged; Obstetrics/Perinatology/Midwifery; Original; Original Article; Pilot Projects; Preoperative Period; PTEN Phosphohydrolase - metabolism; Receptors, Progesterone - metabolism; Reproductive Medicine; Estrogen receptor; Metformin; Endometrial cancer; Progesterone receptor; KLF9
• ISSN: 1933-7191; 1933-7205
• DOI: 10.1007/s43032-019-00019-2

Metformin (MET) is increasingly implicated in reducing the incidence of multiple cancer types in patients with diabetes. However, similar effects of MET in non-diabetic women with endometrial cancer (EC) remain unknown. In a pilot study, obese non-diabetic women diagnosed with type 1, grade 1/2 EC, and consenting to participate were randomly assigned to receive MET or no MET (control (CON)) during the pre-surgical window between diagnosis and hysterectomy. Endometrial tumors obtained at surgery (MET, n  = 4; CON, n  = 4) were analyzed for proliferation (Ki67), apoptosis (TUNEL), and nuclear expression of ERα, PGR, PTEN, and KLF9 proteins in tumor glandular epithelial (GE) and stromal (ST) cells. The percentages of immunopositive cells for PGR and for KLF9 in GE and for PTEN in ST were higher while those for ERα in GE but not ST were lower, in tumors of MET vs. CON patients. The numbers of Ki67- and TUNEL-positive cells in tumor GE and ST did not differ between groups. In human Ishikawa endometrial cancer cells, MET treatment (60 μM) decreased cell numbers and elicited distinct temporal changes in ESR1 , KLF9 , PGR , PGR-B , KLF4 , DKK1 , and other tumor biomarker mRNA levels. In the context of reduced KLF9 expression (by siRNA targeting), MET rapidly amplified PGR , PGR-B , and KLF4 transcript levels. Our findings suggest that MET acts directly in EC cells to modify steroid receptor expression and signaling network and may constitute a preventative strategy against EC in high-risk non-diabetic women.